TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Participants Who Discontinued Study Due to an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of women who lose 10% of baseline BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Number of Coughs Per Hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient-reported productivity loss
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Changes in clinical and biochemical indicators of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bowel cleanness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants With Major Cytogenetic Response (MCyR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With Major Hematologic Response (MaHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: complete remission rate of acute GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Successful hysteroscopic tubal occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ≥ 3 log drop in CFUs of P. aeruginosa in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Xerostomia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in symptoms and function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of Diaper Dermatitis/Rash
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of Urinary Tract Infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: neural activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AOFAS score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Neural Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Relative Dose Intensity - End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Dose Intensity - Mid Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in MADRS Total Score from Baseline to Day 8
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in MADRS Total Score from Baseline to Day 15
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effectiveness of APD and FMPD/APD Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of operative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with interventional radiology
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants with ultrasound aspiration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in acceptance of food
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete or partial lack of remission (LAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of acute renal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in Patient Health Questionnaire (PHQ-9) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Development and progression of COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Plasma drug-level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Treatment Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical change of eyebrow hypotrichosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Symptomatic Atrial Tachycardia/Atrial Fibrillation Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infant Intake (mL) During the Observed Feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant Weight-for-length Z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PFS Proportion Achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of non-sustained wide QRS complex tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: First Phase of Insulin Secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Second Phase of Insulin Secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in baseline Foot and Ankle Ability Measure (FAAM)- Activities of Daily Living (ADL) Subscale at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline Foot and Ankle Ability Measure (FAAM)- Sport subscale at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-free survival percentage
Endpoint domain: Mortality/survival
Primary endpoint: Grade of specific types of toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: MTD of multitargeted tyrosine kinase inhibitor PLX3397
Endpoint domain: Adverse events/effects
Primary endpoint: Viable granulation tissue achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of injection related side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Level of injection related discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: prevention of therapy-related weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in levels of gut microbiome derived metabolites in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in levels of gut microbiome derived metabolites in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in levels of structurally related epicatechin metabolites in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in levels of structurally related epicatechin metabolites in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Auditory verbal learning performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of Erection Questionnaire (QEQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Measured Serum Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Zero to Infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in EKG parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in PGP intensity related to motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dialytic removal of indoxyl sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Response to 'Relieving the Discomfort of Dry Mouth'
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent of Participants Retained
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Delta % changes in binding potential nondisplaceable (%ΔBPnd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Have a Symptomatic RT-qPCR Confirmed SARS-CoV-2 Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Subsequently Develop Signs and Symptoms Within 14 Days of a Positive RT-qPCR
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative WBA (change in Mtb log CFU per day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Trough Forced Expiratory Volume in One Second (Trough FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Symptoms control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breastfeeding behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: data record
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Change in Adult Investigator Symptom Rating Scale (AISRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of MT-1303
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of MT-1303 metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of TMC435 formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WILD 5 Wellness Scale (W5WS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Biomarkers in aqueous humor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of readmissions to the hospital for BPD exacerbation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Workload of physicians
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in 20 Watt Exercise Pulmonary Vascular Resistance (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Erection Quality Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Diagnostic accuracy of BNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Adverse Events Graded by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Changes From Baseline in Clinical Laboratory Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically Meaningful Changes From Baseline in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End tidal sevoflurane concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change From Baseline in the Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change From Baseline in the Vaginal pH at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change From Baseline in the Severity of Self-reported Most Bothersome Symptom (MBS) of Vaginal Dryness at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lymphedema Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Increase in particle counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute ischemic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cumulative incidence of dehiscence
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of Primary Graft Dysfunction (PGD) Grade 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Donor engraftment as measured by chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major toxicities as graded by the CTC v4
Endpoint domain: Adverse events/effects
Primary endpoint: Total Nasal Symptoms Score (TNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5 year local recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Time in Target Range (TIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness of TOL101 to target and downregulate T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concordance in lumbar spine measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sweet taste ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sugar detection thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of alveolar fluid clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Psycho-motor Vigilance Testing (PVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amygdala response to neutral facial expressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Severity of Delayed Nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants According to Treatment Lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Primary or Recurrent Metastatic Breast Cancer Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor Size at Palbociclib Initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Decrease in Leakage Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of BMS-690514
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radioactivity in plasma and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Chewing Swallowing Inventory (CSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in The Mini Nutritional Assessment (MNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the Depression Subscale of Hospital Anxiety and Depression Scale (HADS-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: tumor uptake and retention of [18F] Fluciclatide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Free-water Accumulation in the Substantia Nigra
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Blood Oxygen Level-dependent (BOLD) Signal in the Posterior Putamen, M1, and Supplementary Motor Area (SMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: acute and tardive toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Retinal thickness measurement repeatability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phase II time constant of pulmonary oxygen uptake kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time constant for muscle deoxygenation kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ICU care process
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Opioid Pills Dispensed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participants with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients achieving clinically inactive posterior segment uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to achieve clinically inactive posterior segment uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total sum score of Clinical signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of AZD7687
Endpoint domain: Adverse events/effects
Primary endpoint: Affirmative Response to C-SSRS: Suicidal Ideation
Endpoint domain: Adverse events/effects
Primary endpoint: Probability of clinical pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Percentage of patients in remission or LLDAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-hour Morphine Milligram Equivalents (MME)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ceftaroline Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK/PD Target Attainment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in general Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Beta Catenin Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in duration of pacing-induced atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the plasma concentration curve (AUC0-72)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Peak Rate of Oxygen (VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite measure of motor evoked responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Quality of life as assessed by the Self Geriatric Assessment Measure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prescriptions for AUD
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sustained Viral Load Response (SVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective radiation dose
Endpoint domain: Adverse events/effects
Primary endpoint: fMRI results of specific brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative standing pain at day 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolactin hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Frequency of Mtb antigen-specific IFNγ-producing T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Reaching a Liver Iron Concentration (LIC) < 5 mg Fe/g dw
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tinetti balance and gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of personality traits
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression Rating Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients successfully completing treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels During ABT-333 Monotherapy Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels Through Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Having Treatment-emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Primary thumb stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of common infectious diseases
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With 20% Improvement in ASAS 20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Female Sexual Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum tolerated dose of claudiximab
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline total score of the psychological Unified Huntington's Disease Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients with device related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: kinetic of BCR-ABL load after transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Anti-infectives concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes